GenVec: peers
GenVec beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
GenVec, Mereo BioPharma Group plc, Lipella Pharmaceuticals Inc., Vaccinex, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | GenVecbase GNVC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Mereo BioPharma Group plc MREO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Lipella Pharmaceuticals Inc. LIPO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Yarrow Bioscience, Inc. YARW · 🇺🇸 US Percentile in Healthcare Percentile in USA | Cardiff Oncology, Inc. CRDF · 🇺🇸 US Percentile in Healthcare Percentile in USA | PMGC Holdings Inc. ELAB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Vaccinex, Inc. VCNX · 🇺🇸 US Percentile in Healthcare Percentile in USA | MediciNova, Inc. MNOV · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | —— | —— | $6 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 6 | $307 MOct 28, 2026 · Market data1st of 6 | $71 MOct 30, 2026 · Market data3rd of 6 | $24 MOct 14, 2026 · Market data4th of 6 | $9 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 6 | $74 MOct 16, 2026 · Market data2nd of 6 | $47 M6 ranked |
| Revenue (Better neither way: ranked highest first) | $1 MFY2016 · SEC6th of 8 | $1 MFY2025 · SEC7th of 8 | $1 MFY2024 · SEC5th of 8 | $1 MFY2025 · SEC4th of 8 | $1 MFY2025 · SEC2nd of 8 | $1 MFY2025 · SEC2nd of 8 | $1 MFY2024 · SEC1st of 8 | $0 MFY2025 · SEC8th of 8 | $1 M8 ranked |
| Net income (Higher is better) | $-6 MFY2016 · SEC2nd of 8 | $-42 MFY2025 · SEC7th of 8 | $-5 MFY2024 · SEC1st of 8 | $-26 MFY2025 · SEC6th of 8 | $-46 MFY2025 · SEC8th of 8 | $-8 MFY2025 · SEC3rd of 8 | $-19 MFY2024 · SEC5th of 8 | $-12 MFY2025 · SEC4th of 8 | $-15 M8 ranked |
| Employees (Better neither way: ranked highest first) | 15February 28, 2017 · Profile3rd of 4 | —— | —— | 10December 31, 2025 · Profile4th of 4 | —— | 32December 31, 2025 · Profile1st of 4 | 23December 31, 2024 · Profile2nd of 4 | —— | 194 ranked |
| Margins and returns | |||||||||
| Return on equity (Higher is better) | ———— | -82.2%FY2025 · SEC4th of 630th12th | -198.4%FY2024 · SEC6th of 610th4th | -66.3%FY2025 · SEC2nd of 635th15th | -71.5%FY2025 · SEC3rd of 633rd14th | -106.9%FY2025 · SEC5th of 623rd10th | ———— | -25.5%FY2025 · SEC1st of 657th25th | -76.8%6 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | 625.6×price Oct 28, 2026 · Market data1st of 499th100th | 128.7×price Oct 30, 2026 · Market data3rd of 495th98th | 40.9×price Oct 14, 2026 · Market data4th of 490th97th | ———— | 181.2×price Oct 16, 2026 · Market data2nd of 496th99th | 155.0×4 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | 11.0×price Oct 28, 2026 · Market data1st of 486th90th | 1.6×price Oct 30, 2026 · Market data4th of 432nd38th | 3.1×price Oct 14, 2026 · Market data2nd of 450th63rd | ———— | 1.8×price Oct 16, 2026 · Market data3rd of 436th43rd | 2.4×4 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | -10.8%price Oct 28, 2026 · Market data1st of 441st20th | -53.6%price Oct 30, 2026 · Market data4th of 417th7th | -26.4%price Oct 14, 2026 · Market data3rd of 428th12th | ———— | -13.2%price Oct 16, 2026 · Market data2nd of 439th18th | -19.8%4 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | 0.0×FY2025 · SEConly one with it5th3rd | ———— | ———— | ———— | ———— | 0.0×— |
| Interest cover (Higher is better) | ———— | -154.3×FY2025 · SEConly one with it10th4th | ———— | ———— | ———— | ———— | ———— | ———— | -154.3×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 2 of 8FY2025 · Scorecard4th of 7 | 1 of 6FY2024 · Scorecard5th of 7 | 6 of 17FY2025 · Scorecard1st of 7 | 2 of 15FY2025 · Scorecard6th of 7 | 1 of 9FY2025 · Scorecard7th of 7 | 3 of 9FY2024 · Scorecard2nd of 7 | 4 of 14FY2025 · Scorecard3rd of 7 | 25% passed7 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | 0 of 5FY2025 · Scorecard3rd of 4 | 1 of 5FY2025 · Scorecard1st of 4 | 0 of 5FY2025 · Scorecard3rd of 4 | —— | 1 of 5FY2025 · Scorecard1st of 4 | 10% passed4 ranked |
| Growth checks (Higher is better) | —— | 1 of 2FY2025 · Scorecard2nd of 6 | 0 of 1FY2024 · Scorecard5th of 6 | 1 of 3FY2025 · Scorecard4th of 6 | 0 of 3FY2025 · Scorecard5th of 6 | —— | 2 of 3FY2024 · Scorecard1st of 6 | 1 of 2FY2025 · Scorecard2nd of 6 | 42% passed6 ranked |
| Profitability checks (Higher is better) | —— | 0 of 2FY2025 · Scorecard1st of 7 | 0 of 2FY2024 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0 of 2FY2025 · Scorecard1st of 7 | 0 of 2FY2024 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 2FY2024 · Scorecard2nd of 7 | 4 of 5FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 2FY2025 · Scorecard2nd of 7 | 1 of 3FY2024 · Scorecard4th of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 33% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | 0 of 1FY2025 · Scorecard3rd of 6 | 0 of 1FY2024 · Scorecard3rd of 6 | 1 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard3rd of 6 | —— | 0 of 1FY2024 · Scorecard3rd of 6 | 1 of 1FY2025 · Scorecard1st of 6 | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | 61.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 23.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 0.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | —— | 16.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 19.9%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | 492026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 752026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 62026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | —— | 382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 444 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | -11.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 2 | —— | —— | -0.5 pp2026-Q2 against 2026-Q1 · 13F1st of 2 | -6.1 pp2 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = GenVec: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Mereo BioPharma Group plc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Lipella Pharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Yarrow Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cardiff Oncology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; PMGC Holdings Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vaccinex, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; MediciNova, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Return on equity#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Return on equity | In its sector | In its country |
|---|---|---|---|
| GenVec | — | — | — |
| Mereo BioPharma Group plc | -82.2%FY2025 | 30th percentile in Healthcaremedian -36.9%, 977 companies | 12th percentile in USAmedian 4.8%, 3,580 companies |
| Lipella Pharmaceuticals Inc. | -198.4%FY2024 | 10th percentile in Healthcaremedian -36.9%, 977 companies | 4th percentile in USAmedian 4.8%, 3,580 companies |
| Yarrow Bioscience, Inc. | -66.3%FY2025 | 35th percentile in Healthcaremedian -36.9%, 977 companies | 15th percentile in USAmedian 4.8%, 3,580 companies |
| Cardiff Oncology, Inc. | -71.5%FY2025 | 33rd percentile in Healthcaremedian -36.9%, 977 companies | 14th percentile in USAmedian 4.8%, 3,580 companies |
| PMGC Holdings Inc. | -106.9%FY2025 | 23rd percentile in Healthcaremedian -36.9%, 977 companies | 10th percentile in USAmedian 4.8%, 3,580 companies |
| Vaccinex, Inc. | — | — | — |
| MediciNova, Inc. | -25.5%FY2025 | 57th percentile in Healthcaremedian -36.9%, 977 companies | 25th percentile in USAmedian 4.8%, 3,580 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | GenVec | Mereo BioPharma Group plc | Lipella Pharmaceuticals Inc. | Yarrow Bioscience, Inc. | Cardiff Oncology, Inc. | PMGC Holdings Inc. | Vaccinex, Inc. | MediciNova, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $1 MSEC4th | — | $1 MSEC3rd | $1 MSEC1st | $1 MSEC1st | — | $0 MSEC5th |
| 2024 | — | — | $1 MSEC3rd | $1 MSEC4th | $1 MSEC1st | — | $1 MSEC2nd | — |
| 2023 | — | $10 MSEC1st | $0 MSEC6th | $0 MSEC7th | $0 MSEC5th | $2 MSEC2nd | $1 MSEC4th | $1 MSEC3rd |
| 2022 | — | — | $0 MSEC5th | $0 MSEC2nd | $0 MSEC3rd | $1 MSEC1st | $0 MSEC4th | — |
| 2021 | — | — | $0 MSEC5th | $1 MSEC2nd | $0 MSEC4th | — | $1 MSEC3rd | $4 MSEC1st |
| 2020 | — | — | — | $21 MSEC1st | $0 MSEC3rd | — | $1 MSEC2nd | — |
| 2019 | — | — | — | $0 MSEC2nd | $0 MSEC3rd | — | $1 MSEC1st | — |
| 2018 | — | — | — | $11 MSEC1st | $0 MSEC3rd | — | $1 MSEC2nd | — |
| 2017 | — | — | — | $5 MSEC1st | $1 MSEC2nd | — | — | — |
| 2016 | $1 MSEC2nd | — | — | $1 MSEC1st | $0 MSEC3rd | — | — | — |
| 2015 | $1 MSEC1st | — | — | — | $0 MSEC2nd | — | — | — |
| 2014 | $6 MSEC1st | — | — | — | $0 MSEC2nd | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of GenVec#
Companies of the same industry, within a hundred times its size (latest annual revenue), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Mereo BioPharma Group plcMREO · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on filerevenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Lipella Pharmaceuticals Inc.LIPO · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6 M (last known, Jan 5, 2024) · revenue $1 M (year to December 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Yarrow Bioscience, Inc.YARW · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $307 M (Oct 28, 2026) · revenue $1 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Cardiff Oncology, Inc.CRDF · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $71 M (Oct 30, 2026) · revenue $1 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- PMGC Holdings Inc.ELAB · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $24 M (Oct 14, 2026) · revenue $1 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Vaccinex, Inc.VCNX · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jan 5, 2024) · revenue $1 M (year to December 2024)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- MediciNova, Inc.MNOV · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $74 M (Oct 16, 2026) · revenue $0 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Bio Green Med Solution, Inc.BGMS · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6 M (Oct 26, 2026) · revenue $1 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- Provectus Biopharmaceuticals Inc.PVCT · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $46 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- ImageneBio, Inc.IMA · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $50 M (Oct 27, 2026) · revenue $1 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Seres Therapeutics, Inc.MCRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Allarity Therapeutics, Inc.ALLR · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 15, 2026) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.